- Home
- ALDX vs CRVS Comparison
ALDX vs CRVS Comparison
Compare ALDX & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- CRVS
- Stock Information
- Founded
- ALDX 2004
- CRVS 2014
- Country
- ALDX United States
- CRVS United States
- Employees
- ALDX N/A
- CRVS N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- ALDX Health Care
- CRVS Health Care
- Exchange
- ALDX Nasdaq
- CRVS Nasdaq
- Market Cap
- ALDX 304.9M
- CRVS 257.0M
- IPO Year
- ALDX 2014
- CRVS 2016
- Fundamental
- Price
- ALDX $6.35
- CRVS $4.62
- Analyst Decision
- ALDX Strong Buy
- CRVS Strong Buy
- Analyst Count
- ALDX 2
- CRVS 5
- Target Price
- ALDX $10.00
- CRVS $12.38
- AVG Volume (30 Days)
- ALDX 560.3K
- CRVS 638.5K
- Earning Date
- ALDX 05-01-2025
- CRVS 03-18-2025
- Dividend Yield
- ALDX N/A
- CRVS N/A
- EPS Growth
- ALDX N/A
- CRVS N/A
- EPS
- ALDX N/A
- CRVS N/A
- Revenue
- ALDX N/A
- CRVS N/A
- Revenue This Year
- ALDX N/A
- CRVS N/A
- Revenue Next Year
- ALDX N/A
- CRVS N/A
- P/E Ratio
- ALDX N/A
- CRVS N/A
- Revenue Growth
- ALDX N/A
- CRVS N/A
- 52 Week Low
- ALDX $2.71
- CRVS $1.30
- 52 Week High
- ALDX $6.92
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- ALDX 55.70
- CRVS 50.38
- Support Level
- ALDX $4.78
- CRVS $3.81
- Resistance Level
- ALDX $6.52
- CRVS $4.24
- Average True Range (ATR)
- ALDX 0.53
- CRVS 0.28
- MACD
- ALDX -0.06
- CRVS 0.06
- Stochastic Oscillator
- ALDX 73.36
- CRVS 69.23
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).